National Health Services in the UK has just launched a five-minute cocktail infusion for patients with HER2 positive breast cancer in lieu of the traditional 3-hour Chemotherapy infusion that required longer stay at the Hospital and increasing COVID exposure risks. PHESGO (combination of pertuzumab and trastuzumab) will be a welcome for these patients who account for 15% of breast cancer patients. Many have expressed relief looking forward to spending more time watching and playing cricket instead!  Perhaps this can receive approval across the pond soon!